Historically, androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer has comprised the mainstay of systemic therapy in this primary prostate cancer, often in combination with androgen receptor signaling inhibition (ARSI) with abiraterone, enzalutamide, or apalutamide, with or without docetaxel [80]. This evidence concerns the gene AR and prostate carcinoma.